Telmisartan is a potent target for prevention and treatment in human prostate cancer

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 295-300

  Funao, Kiyoaki ^a   Matsuyama, Masahide ^a,d   Kawahito, Yutaka ^b   Sano, Hajime ^c   Chargui, Jamel ^d   Touraine, Jean Louis ^d   Nakatani, Tatsuya ^a   Yoshimura, Rikio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Angiotensin II receptor blocker; Apoptosis; Peroxisome proliferator activated receptor (PPAR) ; Prostate cancer; Telmisartan

Indexed keywords

CANDESARTAN; HOE 33342; IRBESARTAN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; VALSARTAN;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; STROMA CELL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; MALE; PPAR GAMMA; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 48749090567     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000006     Document Type: Article

References (37)

1. Oh WK and Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160: 1220-1229, 1998.
2. See S and Stirling AL: Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm 57: 739-746, 2000.
3. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
4. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
5. Le Noble FA, Hekking JW, van Straaten HW, Slaaf DW and Struyker Boudier HA: Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick embryo. Eur J Pharmacol 195: 305-306, 1991.
6. Le Noble FA, Schreurs NH, van Straaten HW, et al: Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 264: 460-465, 1993.
7. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43: 993-1002, 2004.
8. Chinetti G, Griglio S, Antonucci M, et al: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580, 1998.
9. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998.
10. Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470, 1998.
11. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPAR-gamma. Nat Med 4: 1046-1052, 1998.
12. Tsubouchi Y, Sano H, Kawahito Y, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 270: 400-405, 2000.
13. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I and Kohgo Y: Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455: 135-139, 1999.
14. Altiok S, Xu M and Spiegelman BM: PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11: 1987-1998, 1997.
15. Bishop-Bailey D and Hla T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274: 17042-17048, 1999.
16. Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287: 727-732, 2001.
17. Yoshimura R, Matsuyama M, Segawa Y, et al: Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104: 597-602, 2003.
18. Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51: 108-116, 2002.
19. Hase T, Yoshimura R, Mitsuhashi M, et al. Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 60: 542-547, 2002.
20. Yoshimura R, Matsuyama M, Hase T, et al: The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells, Int J Mol Med 12: 861-865, 2003.
21. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 103: 904-912, 2001.
22. Dina R and Jafari M: Angiotensin II-receptor antagonists. Am J Health Syst Pharm 57: 1231-1241, 2000.
23. Abali H, Güllü H, Engin H, Haznedaroglu C, Erman M and Tekuzman G: Old antihypertensive as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses 59: 344-348, 2002.
24. Fujimoto Y, Sasaki T, Tsuchida A and Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495: 197-200, 2001.
25. Miyajima A, Kosaka T, Asano T, et al: Angiotensin II type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179, 2002.
26. Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM and Novick AC: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 151: 208-213, 1994.
27. Inwang ER, Puddefoot JR, Brown CL, et al: Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 75: 1279-1283, 1997.
28. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y and Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12: 2888-2893, 2006.
29. Kosaka T, Miyajima A, Takayama E, et al: Angiotensin II type I receptor antagonist as an aongiogenic inhibitor in prostate cancer. Prostate 67: 41-49, 2007.
30. Egami K, Murohara T, Shimada T, et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75, 2003.
31. Koh WP, Yuan JM, van den Berg D, Lee HP and Yu MC: Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26: 459-464, 2005.
32. Uemura H, Hasumi H, Kawahara T, et al: Pilot study of angiotensin II receptor blocker in advanced hormone-refractoiy prostate cancer. Int J Clin Oncol 10: 405-410, 2005.
33. Kawahito Y, Kondo M, Tsubouchi Y, et al: 15-Deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106: 189-197, 2000.
34. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G and Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887, 1992.
35. Kliewer SA, Umesono K, Noonan DJ, Heyman RA and Evans EM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774, 1992.
36. Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
37. Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS and Mitchell MD: 15-Deoxy-Delta (12, 14)-prostaglandin J (2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 262: 579-585, 1999.